Author Archives: Margarida Azevedo, MSc

Idiopathic Pulmonary Fibrosis Trial to Test Combination of Existing Treatments

Boehringer Ingelheim Pharmaceuticals, Inc., recently announced the initiation of a trial to compare the safety, tolerability, and pharmacokinetics of adding pirfenidone (Esbriet) to treatment with OFEV (nintedanib, Boehringer Ingelheim) in patients with idiopathic pulmonary fibrosis (IPF). IPF, a type of interstitial lung disease affecting the tissue that supports the…

Long-Term IPF Treatment with OFEV® (Nintedanib) Shown to Remain Effective and Without New Safety Concerns

New data from the analysis of trial INPULSIS™-ON, describing the long-term efficacy and side-effects of OFEV in the treatment of idiopathic pulmonary fibrosis (IPF), was presented at the European Respiratory Society (ERS) International Congress 2015. IPF is a type of interstitial lung disease, affecting the tissue that supports the alveoli…